In a study published in The Journal of Clinical Investigation, University of Michigan researchers found a new protein target ...

Lung cancer is the second-most common cancer and the leading cause of cancer death in the United States. Over 80% of lung ...

Among survivors of non-small cell lung cancer, nearly 8% developed non-lung secondary cancers over about 6 years, and this ...

J&J has hypothesized that subcutaneous absorption of the drug may potentially enhance immune-mediated anticancer activity.

Martin Dietrich, MD, PhD, a medical oncologist at the Cancer Care Centers of Brevard and an assistant professor at the ...

Sevabertinib showed promise in early trials for non-squamous non-small-cell lung cancer with HER2 mutations. Read more at ...

Mucommune, a Morrisville-based biotechnology company with roots at the University of North Carolina at Chapel Hill, has been ...

Medicaid expansion is associated with lower 2- and 4-year mortality among patients with resectable non-small cell lung cancer ...

If you or a loved one has lung cancer, you may be interested in learning more about medicines used to treat it. One option is an immunotherapy medicine called Imfinzi (durvalumab). Immunotherapy ...

Like all forms of cancer, lung cancer is defined by uncontrolled cell division caused by loss of physiological tissue homeostasis and failure of apoptotic cell death mechanisms. Aberrant cell ...

TROPION-Lung17 Clinical Update: What Investors Should Watch in AstraZeneca and Daiichi Sankyo’s Next Lung Cancer Catalyst ...

Small cell lung cancer (SCLC) is a fast-growing cancer that forms in the lung. It's one of two types of lung cancer. The other type is non-small cell lung cancer (NSCLC). SCLC is less common than ...